Brain Theranostics: Focus on Drug Delivery and Outcomes
Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 9232
Brain theranostics is an emerging research field, integrating “therapeutics” and “diagnostics”. The theranostics approach provides new modalities to improve the diagnostic specificity of brain diseases and to develop and investigate the efficacy of newly developed or repurposed therapeutic compounds, and of targeted and controlled drug delivery schemes. Such a promising field involves concepts associated with the design of probes to image brain diseases, the development of non-invasive bioimaging modalities with high sensitivity and specificity to track biomarkers, the identification of disease-associated mechanisms, and the engineering of delivery platforms such as nanoformulations and extracellular vesicles to improve delivery across the blood–brain barrier (BBB) for effective treatment outcomes.
The objective of this Special Issue is to invite leading experts in the fields of neurodegenerative diseases, neurodevelopmental disorders, neurobehavioral biology, drug-induced neurotoxicity, bioimaging and nanomedicine to discuss their most recent discoveries, and to share their vision for future development in associated topics. Spontaneous submissions are welcome. Both original unpublished research articles and reviews will be considered.
Topics include, but are not limited to:
- New techniques to improve the blood–brain barrier (BBB) penetration of theranostic molecules;
- Sensitive bioimaging modalities for the detection of brain diseases and/or therapeutic efficacy;
- Nanomedicine for the therapy of brain diseases;
- New developments for controlled or targeted drug delivery to the brain;
- Neurodevelopmental neurotoxicity following in utero exposure to therapeutic drugs and new approaches to improve outcomes;
- Neurobehavioral assessments defining brain diseases and therapeutic outcomes;
- Novel mechanisms underlying brain diseases.
Dr. Aditya N. Bade
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neurodegenerative diseases
- blood–brain barrier
- behavioral tests